| Name | Tilmicosin |
| Classes |
Antiinfective Agent Antibiotic Macrolide |
| Diseases |
Bangla
EnglishTilmicosin
Tilmicosin belongs to the macrolide antibiotic class and works by inhibiting protein synthesis in bacteria, thereby preventing their growth and reproduction. It has a broad spectrum of activity against various gram-positive and gram-negative bacteria.
Tilmicosin is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Haemophilus somnus in beef and non-lactating dairy cattle.
Tilmicosin is administered via injection and is available as a solution for injection. The recommended dosage of tilmicosin is 10 mg/kg of body weight, given once daily for 3-5 consecutive days, either by subcutaneous or intramuscular injection.
Adverse reactions to tilmicosin may include local reactions at the injection site, such as swelling, pain, and inflammation. Systemic reactions may also occur, including diarrhea, vomiting, and decreased appetite. Rarely, more serious adverse reactions may occur, such as anaphylaxis or shock.
- Tilmicosin should not be used in lactating dairy cattle.
- Tilmicosin is not approved for use in horses, pigs, or humans.
- Tilmicosin should not be administered intravenously, as it may cause severe adverse reactions, including death.
- Tilmicosin should be used with caution in animals with impaired liver or kidney function.
- Tilmicosin should not be used in animals with a known hypersensitivity to macrolide antibiotics.
Contraindication
Tilmicosin should not be used in animals with a known hypersensitivity to macrolide antibiotics.
None known.
- Tilmicosin is contraindicated in lactating dairy cattle.
- It should not be used in horses, pigs, or humans.
- Tilmicosin should not be administered intravenously.